←
iOrganBio71 posts
iOrganBio avatar

iOrganBio

@iOrganBio

The Right Cells. Consistently. At Scale.

◷ Joined July 2025▧ 27 Photos and videos
iOrganBio avatar
iOrganBio@iOrganBio·Apr 29

🚧 The status quo of biological model discovery, development, and biomanufacturing is blocking progress on some of humanity’s greatest biomedical breakthroughs. At iOrganBio, we’re re-designing cell model discovery and manufacturing from the ground up, leveraging modern automation and machine learning as fundamental components of our system. Using rapid turnaround scRNA-seq, we are able to digitize cell state and automatically guide stem cell differentiation towards bioequivalency using in vivo cell states as a blueprint. Our platform unlocks the next stage of biotechnological development, treating cells as the complex and dynamic systems that we’ve always known them to be. Join us as we transform the way we use cells to cure disease and forge progress using The Right Cells, Consistently, At Scale. 🌐 Learn more about our tech at iorgan.bio/ ✉️ To start a collaboration with iOB, email partnering@iorgan.bio

2:39
iOrganBio avatar
iOrganBio@iOrganBio·Nov 10

“We are excited to partner with iORGANBIO in contributing to greater efficiency in drug discovery and advancements in cell therapy and regenerative medicine. This new partnership will directly support Mitsui Chemicals’ aim to create new solutions that support life, health and enriched lifestyles,” said Shunsuke Fujii, PhD, General Manager at Mitsui Chemicals. Following last week’s news, we’re excited to share more about our collaboration with Mitsui Chemicals. Mitsui Chemicals brings more than a century of materials science and innovative chemical formulations, including its InnoCell™ cell culture plates. Their highly oxygen-permeable design supports healthier, longer-lasting cultures and more uniform 3D tissues, including iPSC-derived organoids. iOrganBio brings an integrated Physical AI platform built to develop and manufacture consistent human cells at scale. CellHorizon defines the target cell state, while CellDiscovery rapidly explores the experimental design space to find the conditions that reach it. CellTelemetry digitizes every manufactured cell, giving our adaptive manufacturing platform, CellForge, the real-time insight it needs to deliver consistent cells, batch after batch. Together, we aim to: 📷 Enable cell types and complex organoids that have been difficult to manufacture 📷 Control culture conditions to improve the quality and consistency of human cells and organoids 📷 Explore new drug discovery technologies, including efficacy and safety testing, that could complement or replace animal testing 📷 Develop new materials and methods to dynamically interact with cells and precisely guide their behavior Read the full press release here: globenewswire.com/news-relea…

iOrganBio avatar
iOrganBio@iOrganBio·Nov 9

Excited to present three posters at the #ISSCR Disease Modeling & Drug Discovery Symposium, Dec 16–18 in San Diego! Come find us at the poster sessions to see how CellForge™ and CellDiscovery™ are making stem-cell manufacturing adaptive.

Post attachment
iOrganBio avatar
iOrganBio@iOrganBio·Oct 29

Timing couldn’t be better: in September, the FDA made clear animal studies aren’t the only path to safety data before human trials. Reliable human cell models will be key to what comes next. Thank you to the Mitsui Chemicals and 321Catalyst teams for their support!

iOrganBio avatar
iOrganBio@iOrganBio·Oct 29

We’re honored to announce an investment from Mitsui Chemicals Group through 321Catalyst Ventures! In our new collaboration, we’ll pair InnoCell™ plates with our AI-driven, closed-loop platform to make more consistent human cells and organoids for drug screening.

iOrganBio avatar
iOrganBio@iOrganBio·Jun 24

🚀 The launch of NIH’s Office of Research Innovation, Validation, and Application (ORIVA) is a major milestone for the non-animal methods (NAMs) ecosystem. By coordinating NIH-wide efforts to develop, validate, and scale human-based research approaches—and by supporting funding, training, and regulatory translation—ORIVA signals a meaningful shift toward models that are more human-relevant, translatable, and fit for modern biomedical research. At @iOrganBio, we see this as strong momentum for the future of precision cell manufacturing and human-based model systems. As the NAMs ecosystem grows, our focus remains on building reproducible, high-fidelity human cell systems and the data infrastructure needed to make them useful for discovery, disease modeling, and translational research. 📄 Read more about ORIVA at dpcpsi.nih.gov/oriva 🌐 Learn more about iOB at iorgan.bio

iOrganBio avatar
iOrganBio@iOrganBio·Jun 11

The @EU_Commission has taken another significant step toward modernizing biomedical research and safety assessment with its newly released roadmap for phasing out animal testing under the REACH framework. This initiative outlines a coordinated strategy to accelerate the development, validation, and regulatory acceptance of New Approach Methodologies (NAMs), reinforcing a growing commitment to more human-relevant science across Europe, and joining a worldwide movement now including: 🇺🇲 USA: bit.ly/441TgYK 🇬🇧 UK: bit.ly/4emJjdj 🇯🇵 Japan: bit.ly/3QB2SXt 🇪🇺 Europe: bit.ly/3Sz07X8 @iOrganBio is helping our partners across the globe navigate this rapidly evolving NAMs landscape by enabling rapid protocol discovery and process development with CellDiscovery™ and scalable cell and organoid manufacturing using CellForge™. With in vitro model quality and consistency more important than ever, we’re proud to be delivering The Right Cells, Consistently, At Scale. 🌐 Learn more about our technology at iorgan.bio #NAMs #Organoids #AnimalTesting #DrugDevelopment #EU

iOrganBio avatar
iOrganBio@iOrganBio·Jun 9

🌴 Get Ready SoCal! We’re just two weeks away from BIO International Convention, and @iOrganBio is excited to be joining the rest of the biotechnology world as we convene in San Diego! Join iOB CEO @DanielDelubac and COO @karol_jarzabek at BIO to learn more about how iOB is revolutionizing how we design and manufacture cells. As adoption of New Approach Methodologies (NAMs) and Non-Animal Technologies (NATs) accelerates, one of the major causes of delay is the lack of precision and reliability in the R&D process. Models that better predict human therapeutic response with consistency and reliability are needed in order to maintain the momentum. At iORGANBIO, we’re leveraging deep transcriptomics and machine learning to control cell fate. Whether unlocking new levels of bioequivalency with CellDiscovery™ or manufacturing cells and organoids with unparalleled reliability using CellForge™, we’re pushing progress forward with The Right Cells, Consistently, At Scale. 🤝 Set up a meeting with the iOB team by emailing partnering@iorgan.bio 🧬 More about #BIO2026 at convention.bio.org/landing?g… 🌐 More about iOB at iorgan.bio #NAMs #Organoids #DrugDiscovery #Biopharma @NCLifeSci

Post attachment
iOrganBio avatar
iOrganBio@iOrganBio·Jun 4

🦓 Progress in the rare disease space is accelerating like never before! Catch the @iOrganBio team next week in Boston at the 2026 World Orphan Drug Congress as we connect with other innovators who are tackling some of the biggest challenges in medicine. COO @karol_jarzabek and BD Lead Lucas Abbott will be in Boston to share how iOB’s CellDiscovery™ Platform is enabling generation of personalized drug discovery models and powering n-of-one clinical trials for rare diseases, and the CellForge™ Platform is enabling scale-out and scale-up of precision cell manufacturing. Together with our partners, we’re helping to transform the approach to rare diseases, unlocking new approaches to personalized therapy development and bringing hope to patients and their loved ones with The Right Cells, Consistently, At Scale. 📝 Register for WODC 2026 at terrapinn.com/conference/wor… 🌐 Learn more about iOB’s technology at iorgan.bio/ ✉️ Explore partnering opportunities by emailing partnering@iorgan.bio #RareDisease #OrphanDrugs #WODC #PersonalizedMedicine #Nof1 @orphan_drugs @OrphanConf

Post attachment
iOrganBio avatar
iOrganBio@iOrganBio·Jun 2

iOrganBio is excited to share the addition of Zhiping Pang to our Scientific Advisory Board. As one of the world’s foremost experts in human neuron biology, synaptic function, and the molecular mechanisms underlying neuropsychiatric and metabolic disorders, Dr. Pang has co-authored over 140 publications in top journals. As @iOrganBio continues to build our technology platform, we’re grateful to have expertise and guidance from the world’s foremost scientists, engineers, and industry leaders. Together, we’re proud to be re-shaping how cell-based research and therapies are developed, expanding access to life changing therapeutics. 🚀 Welcome aboard Zhiping! 📰 Read the full press release at iorganbio.reportablenews.com… 🌐 Learn more about iOB’s technology at iorgan.bio #Neuroscience #Organoids #NAMs #DrugDiscovery #DrugDevelopment

iOrganBio avatar
iOrganBio@iOrganBio·May 26

⚡ In a rapidly changing landscape of biological modeling, agility and evidence-based decision-making are essential for new regulatory frameworks. Earlier this month, the @ISSCR Consortium on Advanced Stem Cell-Based Models in Drug Discovery and Development—with contributions from iOB Co-Founder and Senior Scientific Advisor @ChenShuibing—provided commentary for the @FDA guidance document on NAMs for drug discovery and development. Key highlights included: 🧬 Flexibility in biological complexity and model design 🧩 Fit-for-purpose evaluation beyond comparison to traditional models ⚖️ Clarity of NAM roles within a weight-of-evidence (WoE) framework 🤖 Broader recognition of computational models and AI-integrated NAMs 📐  Right-sizing technical characterization expectations 🔎 Recognizing the unique characteristics of stem cell-derived NAMs iOrganBio applauds ISSCR for this helpful contribution to the regulatory framework. Each of these points intersect with the challenges we are solving; from customized organoid models that allow investigation of previously unavailable biology, to scalability of consistent and reproducible cell manufacturing, to novel insights now possible through the combination of deep transcriptomics and machine learning. 🗞️ Read the ISSCR release at isscr.org/isscr-news/isscr-c… 🌐 Learn more about the iOB tech platform at iorgan.bio ✉️ Reach out to us for partnering opportunities at partnering@iorgan.bio #NAMs #Organoids #Regulatory #FDA #DrugDevelopment #DrugDiscovery

iOrganBio avatar
iOrganBio@iOrganBio·May 18

✍️ Design 🏗️ Build 💥 Test 💡 Learn These are the core engineering principles that guide the iterative design of everything spanning ballpoint pens to fighter jets. And now we can do the same for cells—completely automated—made possible by advanced robotics and AI. As part of Boston Tech Week, @iOrganBio Founder and CEO @DanielDelubac will be contributing to a panel discussing the intersection of deep tech and biomedical progress. Joining him for the Heeding Nature's Call: Reading the Body with AI are: @JohnCapodilupo of @ThroneScience and @WHOOP @LoyConor of @romixbio Moderated by @drewvolpe of @FirstStarVC, this fireside chat promises to be an engaging update on how deep tech is combining with biotechnology to transform human health. If you’re in Boston for @Techweek_ , you won’t want to miss it! 📝 Register for the event at partiful.com/e/MyfKGX0Dl8BiN… 🤖 Check out the full Boston Tech Week lineup at tech-week.com/ 🌐 Learn more about iOB at iorgan.bio/ #BOSTechWeek #AI #Biotech #Organoids #NAMs

iOrganBio avatar
iOrganBio@iOrganBio·May 11

iOrganBio is excited to share the addition of Jessica Owens to our Board of Directors. Bringing with her more than 20 years of experience in the venture capital world, Owens has a proven track record of building companies with impact across technology, life science, and healthcare sectors. As @iOrganBio continues to build our technology platform, we’re grateful to have expertise and guidance from the world’s foremost scientists, engineers, and industry leaders. Together, we’re proud to be re-shaping how cell-based research and therapies are developed, expanding access to life changing therapeutics. 🚀 Welcome aboard Jessica! 📰 Read the full press release at iorganbio.reportablenews.com… 🌐 Learn more about iOB’s technology at iorgan.bio

iOrganBio avatar
iOrganBio@iOrganBio·May 5

We’re proud to congratulate @iOrganBio Co-Founder and Senior Scientific Advisor @ChenShuibing on her re-appointment to the @ISSCR Board of Directors. As highlighted in the ISSCR’s announcement, this recognition reflects Dr. Chen’s continued leadership and influence in advancing stem cell research and regenerative medicine worldwide. Her work sits at the forefront of innovation—bridging fundamental science and translational impact. We’re honored to have her guidance as part of our team and excited to see her ongoing contributions help shape the future of the field. Congratulations, Shuibing! 📄 Full link here isscr.org/isscr-news/the-iss… 🌐 Learn more about iOrganBio and our team at iorgan.bio